[HTML][HTML] Clinical outcomes of ramucirumab plus docetaxel in the treatment of patients with non-small cell lung cancer after immunotherapy: a systematic literature …
EB Garon, C Visseren-Grul, MT Rizzo, T Puri… - Frontiers in …, 2023 - frontiersin.org
Introduction In the REVEL trial, ramucirumab plus docetaxel demonstrated significant
improvements in overall survival (OS), progression-free survival (PFS), and overall response …
improvements in overall survival (OS), progression-free survival (PFS), and overall response …
[HTML][HTML] Current and Emerging Treatment Options for Patients with Metastatic EGFR-Mutated Non-small Cell Lung Cancer After Progression on Osimertinib and …
S Patel, JD Patel - Advances in Therapy, 2023 - Springer
Patients with metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell
lung cancer (NSCLC) are widely treated with osimertinib, the preferred first-line treatment …
lung cancer (NSCLC) are widely treated with osimertinib, the preferred first-line treatment …
[HTML][HTML] Sotorasib in KRASG12C mutated lung cancer–Authors' reply
L Paz-Ares, B Mehta, Y Wang, C Obiozor… - The Lancet, 2024 - thelancet.com
CodeBreaK 2001 was a randomised, open-label phase 3 trial assessing sotorasib's efficacy
compared with docetaxel chemotherapy in patients with KRASG12C advanced non …
compared with docetaxel chemotherapy in patients with KRASG12C advanced non …
[HTML][HTML] CodeBreak 200: study limitations, and future directions
Background In recent years, groundbreaking advancements in lung cancer research have
paved the way for innovative treatments directly targeting KRAS mutations, which have long …
paved the way for innovative treatments directly targeting KRAS mutations, which have long …